证券代码：603122 证券简称：合富中国 公告编号：临 2024-043 合富（中国）医疗科技股份有限公司 关于董事会战略委员会调整为董事会战略与 ESG 委员会并 修订相关议事规则的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日召开了第二届董事会第十三次会议，审议并通过了《关于董事会战略委员 会调整为董事会战略与 ESG 委员会并修订相关议事规则的议案》，现将相关事项 公告如下： 为适应公司战略发展需要，保证公司发展规划和战略决策的科学性和有效性， 增强公司核心竞争力和可持续发展能力，完善公司治理结构，提升公司环境、社 会责任和公司治理（以下简称"ESG"）绩效。根据《中华人民共和国公司法》 《上市公司治理准则》等有关法律、法规、规范性文件以及《合富（中国）医疗 科技股份有限公司公司章程》《合富（中国）医疗科技股份有限公司董事会议事 规则》的规定，并结合公司的实际情况，将原董事会下设专门委员会"董事会战 略委员会"调整为"董事会 ...

第二届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603122 证券简称：合富中国 公告编号：临 2024-041 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会第 十三次会议于 2024 年 10 月 23 日上午在上海市虹漕路 456 号光启大楼 20 楼公 司董事会议室/台北市敦化南路 2 段 76 号 23 楼以现场与视讯相结合的方式召开， 会议通知于 2024 年 10 月 18 日以电子邮件方式发出。本次会议由董事长李惇先 生主持，应到董事 7 人，实到董事 7 人，监事和部分高级管理人员列席了会议。 会议的召开符合《公司法》等法律法规及《公司章程》的规定，会议决议合法、 有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 表决结果：7 票赞成，0 票反对，0 票弃权。 3、审议并通过了《关于使用票据及自有资金等方式支付募投项目所需资金 并以募集资金等额置换 ...

海通证券股份有限公司 关于合富（中国）医疗科技股份有限公司 使用票据及自有资金等方式支付募投项目所需资金 并以募集资金等额置换的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为合富（中 国）医疗科技股份有限公司（以下简称"合富中国"或"公司"）首次公开发行股票 并上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易 所股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规定，对 公司使用部分闲置募集资金进行现金管理的事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074 号）核准，公司首次向社 会公开发行人民币普通股（A 股）股票 9,951.32 万股，本次发行价格为每股人民 币 4.19 元，募集资金总额为人民币 416,960,308.00 元，扣除发行费用人民币（不 含增值税 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2024-042 合富（中国）医疗科技股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届监事会第 十三次会议于 2024 年 10 月 23 日上午在上海市虹漕路 456 号光启大楼 20 楼公 司董事会议室以现场方式召开，会议通知于 2024 年 10 月 18 日以电子邮件方式 发出。会议由监事会主席陈晏女士主持，应到监事 3 人，实到监事 3 人。会议 的召开符合《公司法》等法律法规及《公司章程》的规定，会议决议合法、有 效。 与会监事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、监事会会议审议情况 监事会认为： (一)公司 2024 年第三季度报告的编制和审议程序规范合法，符合法律、法 规、《公司章程》和公司内部管理制度的各项规定，内容真实、准确、完整。 (二) 公司 2024 年第三季度报告的内容和格式符合中国证监会和上海 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2024-044 合富（中国）医疗科技股份有限公司 关于使用票据及自有资金等方式支付募投项目所需资金 并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日召开公司第二届董事会第十三次会议、第二届监事会第十三次会议，分别 审议通过了《关于使用票据及自有资金等方式支付募投项目所需资金并以募集资 金等额置换的议案》，同意公司在募投项目实施期间，使用银行承兑汇票（或背 书转让）、商业承兑汇票（或背书转让）、供应链票据（或背书转让）、信用证等 债权凭证、自有资金等方式支付募投项目部分款项，后续按季度以募集资金等额 置换，并从募集资金专户等额划转至公司基本户及一般户。具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074 号）核准，公司首次向社 会公开发行人民币普通 ...

Financial Performance - Revenue for Q3 2024 was ¥230,169,053.57, a decrease of 14.09% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥4,030,001.72, down 69.34% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥1,011,333.36, a decline of 89.43% compared to the previous year[2] - Basic earnings per share for Q3 2024 was ¥0.01, a decrease of 66.67% year-on-year[3] - Diluted earnings per share for Q3 2024 was also ¥0.01, reflecting a 66.67% decline compared to the same period last year[3] - Total operating revenue for the first three quarters of 2024 was CNY 710,974,440.58, a decrease of 14.7% compared to CNY 833,171,189.81 in the same period of 2023[17] - Net profit for the first three quarters of 2024 was CNY 27,262,389.89, a decline of 38.0% from CNY 44,059,418.79 in the same period of 2023[17] - The company reported a basic earnings per share of CNY 0.07 for the first three quarters of 2024, compared to CNY 0.11 in the same period of 2023[18] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥2,549,482.37, indicating cash flow challenges[2] - Cash flow from operating activities was CNY 789,703,867.87 for the first three quarters of 2024, a decrease of 15.6% from CNY 935,879,513.79 in the same period of 2023[19] - The net cash flow from operating activities was -2,549,482.37 CNY, an improvement from -53,485,130.65 CNY in the previous year[20] - Total cash inflow from operating activities was 824,285,173.74 CNY, compared to 948,675,860.19 CNY in the same period last year[20] - Cash outflow from operating activities totaled 826,834,656.11 CNY, down from 1,002,160,990.84 CNY year-over-year[20] - The net cash flow from investing activities was -16,543,872.16 CNY, a decline from 5,619,894.87 CNY in the previous year[20] - Cash inflow from financing activities was 410,557,416.75 CNY, compared to 331,220,938.30 CNY in the same period last year[20] - The net cash flow from financing activities was 11,681,304.71 CNY, down from 38,197,346.42 CNY year-over-year[21] - The ending cash and cash equivalents balance was 178,478,283.81 CNY, a decrease from 297,623,457.43 CNY in the previous year[21] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,463,503,262.88, a slight increase of 0.14% from the end of the previous year[3] - Total current liabilities are 291,038,822.52 RMB, up from 285,727,628.78 RMB[14] - Non-current liabilities include long-term borrowings of 540,256.52 RMB, down from 2,183,908.04 RMB[14] - The company’s total liabilities amounted to CNY 293,647,159.10, slightly up from CNY 292,494,548.82 in the previous year[17] - Total assets as of September 30, 2024, are 1,463,503,262.88 RMB, compared to 1,461,406,215.62 RMB at the end of 2023[13] - Short-term borrowings increased significantly to 100,537,252.21 RMB from 53,923,772.38 RMB[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 36,754[8] - The largest shareholder, 合富（香港）控股有限公司, holds 55.00% of shares, totaling 218,937,885 shares[8] Operational Changes - The company reduced non-terminal medical product distribution to improve cash flow, impacting short-term revenue and profit[6] - Research and development expenses increased to CNY 2,710,404.48 in the first three quarters of 2024, compared to CNY 2,463,292.64 in the same period of 2023, reflecting a growth of 10.0%[17] Tax and Other Comprehensive Income - The company recorded a tax expense of CNY 9,766,091.58 for the first three quarters of 2024, down from CNY 19,063,741.02 in the same period of 2023[17] - Other comprehensive income after tax for the first three quarters of 2024 was CNY -2,434,794.93, compared to CNY 3,375,980.83 in the same period of 2023[18]

证券代码：603122 证券简称：合富中国 公告编号：临 2024-040 合富（中国）医疗科技股份有限公司董事会 2024 年 10 月 12 日 1 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司营业收入。 本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据以公司定期报 告为准，敬请投资者注意投资风险。 公司 2024 年 1-9 月累计合并营业收入为人民币 71,097.44 万元，较去年同 期的合并营业收入减少 14.67%。 特此公告。 合富（中国）医疗科技股份有限公司 2024 年 1-9 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2024-039 合富（中国）医疗科技股份有限公司 关于 2024 年半年度业绩说明会召开情况的公告 问：请问贵公司是否有回购自家公司股份的想法? 答：您好！公司及管理层对自身的经营前景有信心，董事会以保护投资者权 益为出发点，如公司股价过度异常，将作出必要的裁夺；如有回购公司股票的计 划，将按照法律法规的要求履行相应的审议及披露义务。感谢您对公司的关注！ 问：公司上半年研发投入同期增长较多，请问主要的研发投入在哪些业务领 域？ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"或"合富中国"） 于 2024 年 9 月 11 日（星期三）11:30-12:30 在价值在线网站（https://www.ir- online.cn/）通过网络文字互动的形式召开了公司 2024 年半年度业绩说明会， 现将具体情况公告如下： 一、本次业绩说明会召开情况 公司于 2024 年 9 月 11 日（星期三）11:30-12:30 召开 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2024-038 公司 2024 年 1-8 月累计合并营业收入为人民币 62,237.59 万元，较去年同 期的合并营业收入减少 15.26%。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2024 年 9 月 10 日 1 合富（中国）医疗科技股份有限公司 2024 年 1-8 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司营业收入。 本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据以公 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥480,805,387.01, a decrease of 14.94% compared to the same period last year[19]. - The net profit attributable to shareholders for the same period was ¥22,521,891.77, down 27.18% year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥20,764,127.52, a decline of 29.63% compared to the previous year[19]. - Basic earnings per share decreased to ¥0.06, down 25.00% from ¥0.08 in the previous year[20]. - The weighted average return on net assets was 1.91%, a decrease of 0.73 percentage points year-on-year[20]. - The company's total operating costs for the first half of 2024 were approximately ¥373.72 million, a decrease of 15.0% compared to ¥438.94 million in the same period of 2023[93]. - The net cash flow from operating activities improved to -¥23,392,670.10, compared to -¥74,738,461.70 in the same period last year[19]. - The company reported a net profit for the first half of 2024 of approximately ¥16.69 million, down 43.5% from ¥29.61 million in the first half of 2023[94]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,458,374,850.64, down 0.21% from the previous year[19]. - The company's net assets attributable to shareholders at the end of the reporting period were ¥1,165,256,254.53, a slight decrease of 0.13% from the end of the previous year[19]. - Total current assets as of June 30, 2024, amounted to CNY 1,248,509,857.07, a slight decrease from CNY 1,254,796,468.80 on December 31, 2023, representing a decline of approximately 0.4%[84]. - Total liabilities as of June 30, 2024, were CNY 290,686,758.64, a slight decrease from CNY 292,494,548.82 on December 31, 2023[86]. - The company's total equity as of June 30, 2024, was CNY 1,167,688,092.00, a slight decrease from CNY 1,168,911,666.80[86]. - Cash and cash equivalents decreased by 23.26% to CNY 151,866,681.18, accounting for 10.41% of total assets[43]. - Short-term borrowings increased by 56.56% to CNY 84,425,738.63, representing 5.79% of total assets[43]. Corporate Governance and Compliance - The company guarantees the authenticity, accuracy, and completeness of the semi-annual report[2]. - The report is not audited[3]. - The company did not propose a profit distribution plan or capital reserve transfer plan for the reporting period[4]. - The company has not disclosed any significant changes in its registered address during the reporting period[14]. - The company has not engaged in any violations regarding guarantees during the reporting period[67]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders and the public[66]. - The company guarantees compliance with legal and regulatory requirements in all related party transactions[66]. Market and Strategic Initiatives - The domestic in vitro diagnostic market is expected to continue growing, driven by increasing health awareness and aging population trends[25]. - The company has established a comprehensive integrated service system, focusing on personalized needs of end customers and effectively integrating upstream supplier resources[28]. - The company has signed long-term contracts with medical institutions, providing overall supply chain management services for their reagent and consumable needs[28]. - The company is collaborating with Zhejiang University to create a customized clinical diagnosis assistance system using AI and big data analysis for specific diseases in designated regions[30]. - The company aims to enhance the operational management capabilities of hospitals, aligning with national policies for high-quality development in public hospitals[27]. - The company is focusing on developing autonomous empowerment projects, which have already been implemented, increasing customer loyalty[30]. Research and Development - Research and development expenses increased by 33.87%, reaching ¥2,361,319.14, compared to ¥1,763,887.39 in the previous year[41]. - The company is developing new instruments and upgrading information systems, with the latter project having an investment progress of 76.20%[74]. Environmental and Social Responsibility - The company has implemented measures to promote carbon reduction in daily office operations, although specific CO2 equivalent reductions were not applicable[58]. - The company has adopted waste classification measures in its offices to promote sustainable development and resource utilization[57]. - The company continues to advocate for energy and water conservation, promoting a paperless office environment[57]. - Approximately 25% of the mileage for administrative vehicles during the reporting period was covered by electric vehicles, indicating a shift towards reducing gasoline and diesel consumption[59]. Shareholder and Stock Management - The company will not transfer or manage shares held prior to the IPO for 36 months, with an extension of the lock-up period if stock prices fall below the issue price[63]. - The company plans to stabilize its stock price by implementing buyback measures if the stock price falls below the net asset value per share for 20 consecutive trading days[63]. - The total amount used for share buybacks will not exceed 10% of the previous year's audited net profit attributable to shareholders[63]. - The company has outlined specific conditions under which stock buybacks and shareholder increases will be initiated to maintain compliance with listing requirements[63]. Legal Matters - The company has initiated a lawsuit against Handan Second Hospital for unpaid goods amounting to ¥6,235,285.19, which is currently under execution after mediation[68]. - The company has no significant litigation or arbitration matters pending as of the report period[69]. Financial Reporting and Accounting Policies - The financial statements are prepared on a going concern basis, indicating the company's ability to continue operations for at least 12 months from the reporting date[113]. - The company's financial statements comply with the accounting standards and accurately reflect its financial position and operating results[115]. - The group recognizes revenue when control of goods or services is transferred to customers, which occurs upon delivery and acceptance[151]. - The company assesses the materiality of financial statement disclosures based on a threshold of 5% of pre-tax profit[119].